Market Analysis and Insights: Global Telmisartan Market
Due to the COVID-19 pandemic, the global Telmisartan market size is estimated to be worth US$ 2971.3 million in 2022 and is forecast to a readjusted size of US$ 3631.3 million by 2028 with a CAGR of 3.4% during the review period. Fully considering the economic change by this health crisis, Injection accounting for % of the Telmisartan global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Telmisartan market size is valued at US$ million in 2021, while the US and Europe Telmisartan are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Telmisartan landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Telmisartan include Pfizer, Teva, Boehringer Ingelheim, Novartis, Mylan, Reddy's Laboratories (UK), Hema Pharmaceuticals Pvt, Bayer and GSK, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Telmisartan Scope and Segment
Telmisartan market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Telmisartan market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Injection
Freeze-Dried Powder
Segment by Application
Hospital
Clinic
Others
By Company
Pfizer
Teva
Boehringer Ingelheim
Novartis
Mylan
Reddy's Laboratories (UK)
Hema Pharmaceuticals Pvt
Bayer
GSK
Astellas Pharma Inc
Nippon Boehringer Ingelheim
Abbott
Takeda
Beijing Wansheng Pharmaceutical
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Due to the COVID-19 pandemic, the global Telmisartan market size is estimated to be worth US$ 2971.3 million in 2022 and is forecast to a readjusted size of US$ 3631.3 million by 2028 with a CAGR of 3.4% during the review period. Fully considering the economic change by this health crisis, Injection accounting for % of the Telmisartan global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Telmisartan market size is valued at US$ million in 2021, while the US and Europe Telmisartan are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Telmisartan landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Telmisartan include Pfizer, Teva, Boehringer Ingelheim, Novartis, Mylan, Reddy's Laboratories (UK), Hema Pharmaceuticals Pvt, Bayer and GSK, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Telmisartan Scope and Segment
Telmisartan market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Telmisartan market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Injection
Freeze-Dried Powder
Segment by Application
Hospital
Clinic
Others
By Company
Pfizer
Teva
Boehringer Ingelheim
Novartis
Mylan
Reddy's Laboratories (UK)
Hema Pharmaceuticals Pvt
Bayer
GSK
Astellas Pharma Inc
Nippon Boehringer Ingelheim
Abbott
Takeda
Beijing Wansheng Pharmaceutical
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Frequently Asked Questions
This market study covers the global and regional market with an
in-depth analysis of the
overall growth prospects...
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by
highlighting information on
different aspects including drivers, restraints...
Pre-order Enquiry
Download Free Sample








